 | • レポートコード：MRC2312MG15965 • 出版社/出版日：Market Monitor Global / 2023年12月 • レポート形態：英文、PDF、111ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医療機器＆消耗品 |
| Single User | ￥487,500 (USD3,250) | ▷ お問い合わせ |
| Enterprise User | ￥731,250 (USD4,875) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートは次の情報を含め、世界の遺伝性網膜疾患治療剤市場規模と予測を収録しています。・世界の遺伝性網膜疾患治療剤市場：売上、2018年-2023年、2024年-2029年 ・世界の遺伝性網膜疾患治療剤市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界の遺伝性網膜疾患治療剤市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「遺伝子治療」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 遺伝性網膜疾患治療剤のグローバル主要企業は、Spark Therapeutics、 Novartis、 Okuvision、 NIDEK、 Invitae、 ZEISS INTERNATIONAL、 MeiraGTx、 Neurosoft、 Astellas Pharma、 Bionic Vision Technologies、 Coave Therapeutics、 GenSight Biologics、 Ionis Pharmaceuticals、 IVERIC BIO、 Johnson & Johnson、 LKC Technologies、 Santen Pharmaceutical、 He Eye Hospital、 Bgi Genomicsなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、遺伝性網膜疾患治療剤のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界の遺伝性網膜疾患治療剤市場：タイプ別、2018年-2023年、2024年-2029年 世界の遺伝性網膜疾患治療剤市場：タイプ別市場シェア、2022年 ・遺伝子治療、人工網膜、神経保護剤 世界の遺伝性網膜疾患治療剤市場：用途別、2018年-2023年、2024年-2029年 世界の遺伝性網膜疾患治療剤市場：用途別市場シェア、2022年 ・病院、診療所 世界の遺伝性網膜疾患治療剤市場：地域・国別、2018年-2023年、2024年-2029年 世界の遺伝性網膜疾患治療剤市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業における遺伝性網膜疾患治療剤のグローバル売上、2018年-2023年 ・主要企業における遺伝性網膜疾患治療剤のグローバル売上シェア、2022年 ・主要企業における遺伝性網膜疾患治療剤のグローバル販売量、2018年-2023年 ・主要企業における遺伝性網膜疾患治療剤のグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 Spark Therapeutics、 Novartis、 Okuvision、 NIDEK、 Invitae、 ZEISS INTERNATIONAL、 MeiraGTx、 Neurosoft、 Astellas Pharma、 Bionic Vision Technologies、 Coave Therapeutics、 GenSight Biologics、 Ionis Pharmaceuticals、 IVERIC BIO、 Johnson & Johnson、 LKC Technologies、 Santen Pharmaceutical、 He Eye Hospital、 Bgi Genomics ************************************************************* ・調査・分析レポートの概要 遺伝性網膜疾患治療剤市場の定義 市場セグメント 世界の遺伝性網膜疾患治療剤市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界の遺伝性網膜疾患治療剤市場規模 世界の遺伝性網膜疾患治療剤市場規模：2022年 VS 2029年 世界の遺伝性網膜疾患治療剤市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでの遺伝性網膜疾患治療剤の売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業の遺伝性網膜疾患治療剤製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：遺伝子治療、人工網膜、神経保護剤 遺伝性網膜疾患治療剤のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：病院、診療所 遺伝性網膜疾患治療剤の用途別グローバル売上・予測 ・地域別市場分析 地域別遺伝性網膜疾患治療剤市場規模 2022年と2029年 地域別遺伝性網膜疾患治療剤売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Spark Therapeutics、 Novartis、 Okuvision、 NIDEK、 Invitae、 ZEISS INTERNATIONAL、 MeiraGTx、 Neurosoft、 Astellas Pharma、 Bionic Vision Technologies、 Coave Therapeutics、 GenSight Biologics、 Ionis Pharmaceuticals、 IVERIC BIO、 Johnson & Johnson、 LKC Technologies、 Santen Pharmaceutical、 He Eye Hospital、 Bgi Genomics ... |
This research report provides a comprehensive analysis of the Inherited Retinal Disease Treatment market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Inherited Retinal Disease Treatment market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Inherited Retinal Disease Treatment, challenges faced by the industry, and potential opportunities for market players.
The global Inherited Retinal Disease Treatment market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Inherited Retinal Disease Treatment market presents opportunities for various stakeholders, including Hospital, Clinic. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Inherited Retinal Disease Treatment market. Additionally, the growing consumer demand present avenues for market expansion.
The global Inherited Retinal Disease Treatment market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period.
Key Features:
The research report on the Inherited Retinal Disease Treatment market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Inherited Retinal Disease Treatment market.
Market Overview: The report provides a comprehensive overview of the Inherited Retinal Disease Treatment market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Gene Therapy, Artificial Retina), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Inherited Retinal Disease Treatment market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Inherited Retinal Disease Treatment market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Inherited Retinal Disease Treatment market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Inherited Retinal Disease Treatment market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Inherited Retinal Disease Treatment market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Inherited Retinal Disease Treatment market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Inherited Retinal Disease Treatment, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Inherited Retinal Disease Treatment market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Inherited Retinal Disease Treatment market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Gene Therapy
Artificial Retina
Neuroprotectant
Market segment by Application
Hospital
Clinic
Global Inherited Retinal Disease Treatment Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Spark Therapeutics
Novartis
Okuvision
NIDEK
Invitae
ZEISS INTERNATIONAL
MeiraGTx
Neurosoft
Astellas Pharma
Bionic Vision Technologies
Coave Therapeutics
GenSight Biologics
Ionis Pharmaceuticals
IVERIC BIO
Johnson & Johnson
LKC Technologies
Santen Pharmaceutical
He Eye Hospital
Bgi Genomics
Outline of Major Chapters:
Chapter 1: Introduces the definition of Inherited Retinal Disease Treatment, market overview.
Chapter 2: Global Inherited Retinal Disease Treatment market size in revenue and volume.
Chapter 3: Detailed analysis of Inherited Retinal Disease Treatment manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Inherited Retinal Disease Treatment in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Inherited Retinal Disease Treatment capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Inherited Retinal Disease Treatment Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Inherited Retinal Disease Treatment Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Inherited Retinal Disease Treatment Overall Market Size
2.1 Global Inherited Retinal Disease Treatment Market Size: 2022 VS 2029
2.2 Global Inherited Retinal Disease Treatment Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Inherited Retinal Disease Treatment Sales: 2018-2029
3 Company Landscape
3.1 Top Inherited Retinal Disease Treatment Players in Global Market
3.2 Top Global Inherited Retinal Disease Treatment Companies Ranked by Revenue
3.3 Global Inherited Retinal Disease Treatment Revenue by Companies
3.4 Global Inherited Retinal Disease Treatment Sales by Companies
3.5 Global Inherited Retinal Disease Treatment Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Inherited Retinal Disease Treatment Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Inherited Retinal Disease Treatment Product Type
3.8 Tier 1, Tier 2 and Tier 3 Inherited Retinal Disease Treatment Players in Global Market
3.8.1 List of Global Tier 1 Inherited Retinal Disease Treatment Companies
3.8.2 List of Global Tier 2 and Tier 3 Inherited Retinal Disease Treatment Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Inherited Retinal Disease Treatment Market Size Markets, 2022 & 2029
4.1.2 Gene Therapy
4.1.3 Artificial Retina
4.1.4 Neuroprotectant
4.2 By Type – Global Inherited Retinal Disease Treatment Revenue & Forecasts
4.2.1 By Type – Global Inherited Retinal Disease Treatment Revenue, 2018-2023
4.2.2 By Type – Global Inherited Retinal Disease Treatment Revenue, 2024-2029
4.2.3 By Type – Global Inherited Retinal Disease Treatment Revenue Market Share, 2018-2029
4.3 By Type – Global Inherited Retinal Disease Treatment Sales & Forecasts
4.3.1 By Type – Global Inherited Retinal Disease Treatment Sales, 2018-2023
4.3.2 By Type – Global Inherited Retinal Disease Treatment Sales, 2024-2029
4.3.3 By Type – Global Inherited Retinal Disease Treatment Sales Market Share, 2018-2029
4.4 By Type – Global Inherited Retinal Disease Treatment Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Inherited Retinal Disease Treatment Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Clinic
5.2 By Application – Global Inherited Retinal Disease Treatment Revenue & Forecasts
5.2.1 By Application – Global Inherited Retinal Disease Treatment Revenue, 2018-2023
5.2.2 By Application – Global Inherited Retinal Disease Treatment Revenue, 2024-2029
5.2.3 By Application – Global Inherited Retinal Disease Treatment Revenue Market Share, 2018-2029
5.3 By Application – Global Inherited Retinal Disease Treatment Sales & Forecasts
5.3.1 By Application – Global Inherited Retinal Disease Treatment Sales, 2018-2023
5.3.2 By Application – Global Inherited Retinal Disease Treatment Sales, 2024-2029
5.3.3 By Application – Global Inherited Retinal Disease Treatment Sales Market Share, 2018-2029
5.4 By Application – Global Inherited Retinal Disease Treatment Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Inherited Retinal Disease Treatment Market Size, 2022 & 2029
6.2 By Region – Global Inherited Retinal Disease Treatment Revenue & Forecasts
6.2.1 By Region – Global Inherited Retinal Disease Treatment Revenue, 2018-2023
6.2.2 By Region – Global Inherited Retinal Disease Treatment Revenue, 2024-2029
6.2.3 By Region – Global Inherited Retinal Disease Treatment Revenue Market Share, 2018-2029
6.3 By Region – Global Inherited Retinal Disease Treatment Sales & Forecasts
6.3.1 By Region – Global Inherited Retinal Disease Treatment Sales, 2018-2023
6.3.2 By Region – Global Inherited Retinal Disease Treatment Sales, 2024-2029
6.3.3 By Region – Global Inherited Retinal Disease Treatment Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Inherited Retinal Disease Treatment Revenue, 2018-2029
6.4.2 By Country – North America Inherited Retinal Disease Treatment Sales, 2018-2029
6.4.3 US Inherited Retinal Disease Treatment Market Size, 2018-2029
6.4.4 Canada Inherited Retinal Disease Treatment Market Size, 2018-2029
6.4.5 Mexico Inherited Retinal Disease Treatment Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Inherited Retinal Disease Treatment Revenue, 2018-2029
6.5.2 By Country – Europe Inherited Retinal Disease Treatment Sales, 2018-2029
6.5.3 Germany Inherited Retinal Disease Treatment Market Size, 2018-2029
6.5.4 France Inherited Retinal Disease Treatment Market Size, 2018-2029
6.5.5 U.K. Inherited Retinal Disease Treatment Market Size, 2018-2029
6.5.6 Italy Inherited Retinal Disease Treatment Market Size, 2018-2029
6.5.7 Russia Inherited Retinal Disease Treatment Market Size, 2018-2029
6.5.8 Nordic Countries Inherited Retinal Disease Treatment Market Size, 2018-2029
6.5.9 Benelux Inherited Retinal Disease Treatment Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Inherited Retinal Disease Treatment Revenue, 2018-2029
6.6.2 By Region – Asia Inherited Retinal Disease Treatment Sales, 2018-2029
6.6.3 China Inherited Retinal Disease Treatment Market Size, 2018-2029
6.6.4 Japan Inherited Retinal Disease Treatment Market Size, 2018-2029
6.6.5 South Korea Inherited Retinal Disease Treatment Market Size, 2018-2029
6.6.6 Southeast Asia Inherited Retinal Disease Treatment Market Size, 2018-2029
6.6.7 India Inherited Retinal Disease Treatment Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Inherited Retinal Disease Treatment Revenue, 2018-2029
6.7.2 By Country – South America Inherited Retinal Disease Treatment Sales, 2018-2029
6.7.3 Brazil Inherited Retinal Disease Treatment Market Size, 2018-2029
6.7.4 Argentina Inherited Retinal Disease Treatment Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Inherited Retinal Disease Treatment Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Inherited Retinal Disease Treatment Sales, 2018-2029
6.8.3 Turkey Inherited Retinal Disease Treatment Market Size, 2018-2029
6.8.4 Israel Inherited Retinal Disease Treatment Market Size, 2018-2029
6.8.5 Saudi Arabia Inherited Retinal Disease Treatment Market Size, 2018-2029
6.8.6 UAE Inherited Retinal Disease Treatment Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Spark Therapeutics
7.1.1 Spark Therapeutics Company Summary
7.1.2 Spark Therapeutics Business Overview
7.1.3 Spark Therapeutics Inherited Retinal Disease Treatment Major Product Offerings
7.1.4 Spark Therapeutics Inherited Retinal Disease Treatment Sales and Revenue in Global (2018-2023)
7.1.5 Spark Therapeutics Key News & Latest Developments
7.2 Novartis
7.2.1 Novartis Company Summary
7.2.2 Novartis Business Overview
7.2.3 Novartis Inherited Retinal Disease Treatment Major Product Offerings
7.2.4 Novartis Inherited Retinal Disease Treatment Sales and Revenue in Global (2018-2023)
7.2.5 Novartis Key News & Latest Developments
7.3 Okuvision
7.3.1 Okuvision Company Summary
7.3.2 Okuvision Business Overview
7.3.3 Okuvision Inherited Retinal Disease Treatment Major Product Offerings
7.3.4 Okuvision Inherited Retinal Disease Treatment Sales and Revenue in Global (2018-2023)
7.3.5 Okuvision Key News & Latest Developments
7.4 NIDEK
7.4.1 NIDEK Company Summary
7.4.2 NIDEK Business Overview
7.4.3 NIDEK Inherited Retinal Disease Treatment Major Product Offerings
7.4.4 NIDEK Inherited Retinal Disease Treatment Sales and Revenue in Global (2018-2023)
7.4.5 NIDEK Key News & Latest Developments
7.5 Invitae
7.5.1 Invitae Company Summary
7.5.2 Invitae Business Overview
7.5.3 Invitae Inherited Retinal Disease Treatment Major Product Offerings
7.5.4 Invitae Inherited Retinal Disease Treatment Sales and Revenue in Global (2018-2023)
7.5.5 Invitae Key News & Latest Developments
7.6 ZEISS INTERNATIONAL
7.6.1 ZEISS INTERNATIONAL Company Summary
7.6.2 ZEISS INTERNATIONAL Business Overview
7.6.3 ZEISS INTERNATIONAL Inherited Retinal Disease Treatment Major Product Offerings
7.6.4 ZEISS INTERNATIONAL Inherited Retinal Disease Treatment Sales and Revenue in Global (2018-2023)
7.6.5 ZEISS INTERNATIONAL Key News & Latest Developments
7.7 MeiraGTx
7.7.1 MeiraGTx Company Summary
7.7.2 MeiraGTx Business Overview
7.7.3 MeiraGTx Inherited Retinal Disease Treatment Major Product Offerings
7.7.4 MeiraGTx Inherited Retinal Disease Treatment Sales and Revenue in Global (2018-2023)
7.7.5 MeiraGTx Key News & Latest Developments
7.8 Neurosoft
7.8.1 Neurosoft Company Summary
7.8.2 Neurosoft Business Overview
7.8.3 Neurosoft Inherited Retinal Disease Treatment Major Product Offerings
7.8.4 Neurosoft Inherited Retinal Disease Treatment Sales and Revenue in Global (2018-2023)
7.8.5 Neurosoft Key News & Latest Developments
7.9 Astellas Pharma
7.9.1 Astellas Pharma Company Summary
7.9.2 Astellas Pharma Business Overview
7.9.3 Astellas Pharma Inherited Retinal Disease Treatment Major Product Offerings
7.9.4 Astellas Pharma Inherited Retinal Disease Treatment Sales and Revenue in Global (2018-2023)
7.9.5 Astellas Pharma Key News & Latest Developments
7.10 Bionic Vision Technologies
7.10.1 Bionic Vision Technologies Company Summary
7.10.2 Bionic Vision Technologies Business Overview
7.10.3 Bionic Vision Technologies Inherited Retinal Disease Treatment Major Product Offerings
7.10.4 Bionic Vision Technologies Inherited Retinal Disease Treatment Sales and Revenue in Global (2018-2023)
7.10.5 Bionic Vision Technologies Key News & Latest Developments
7.11 Coave Therapeutics
7.11.1 Coave Therapeutics Company Summary
7.11.2 Coave Therapeutics Business Overview
7.11.3 Coave Therapeutics Inherited Retinal Disease Treatment Major Product Offerings
7.11.4 Coave Therapeutics Inherited Retinal Disease Treatment Sales and Revenue in Global (2018-2023)
7.11.5 Coave Therapeutics Key News & Latest Developments
7.12 GenSight Biologics
7.12.1 GenSight Biologics Company Summary
7.12.2 GenSight Biologics Business Overview
7.12.3 GenSight Biologics Inherited Retinal Disease Treatment Major Product Offerings
7.12.4 GenSight Biologics Inherited Retinal Disease Treatment Sales and Revenue in Global (2018-2023)
7.12.5 GenSight Biologics Key News & Latest Developments
7.13 Ionis Pharmaceuticals
7.13.1 Ionis Pharmaceuticals Company Summary
7.13.2 Ionis Pharmaceuticals Business Overview
7.13.3 Ionis Pharmaceuticals Inherited Retinal Disease Treatment Major Product Offerings
7.13.4 Ionis Pharmaceuticals Inherited Retinal Disease Treatment Sales and Revenue in Global (2018-2023)
7.13.5 Ionis Pharmaceuticals Key News & Latest Developments
7.14 IVERIC BIO
7.14.1 IVERIC BIO Company Summary
7.14.2 IVERIC BIO Business Overview
7.14.3 IVERIC BIO Inherited Retinal Disease Treatment Major Product Offerings
7.14.4 IVERIC BIO Inherited Retinal Disease Treatment Sales and Revenue in Global (2018-2023)
7.14.5 IVERIC BIO Key News & Latest Developments
7.15 Johnson & Johnson
7.15.1 Johnson & Johnson Company Summary
7.15.2 Johnson & Johnson Business Overview
7.15.3 Johnson & Johnson Inherited Retinal Disease Treatment Major Product Offerings
7.15.4 Johnson & Johnson Inherited Retinal Disease Treatment Sales and Revenue in Global (2018-2023)
7.15.5 Johnson & Johnson Key News & Latest Developments
7.16 LKC Technologies
7.16.1 LKC Technologies Company Summary
7.16.2 LKC Technologies Business Overview
7.16.3 LKC Technologies Inherited Retinal Disease Treatment Major Product Offerings
7.16.4 LKC Technologies Inherited Retinal Disease Treatment Sales and Revenue in Global (2018-2023)
7.16.5 LKC Technologies Key News & Latest Developments
7.17 Santen Pharmaceutical
7.17.1 Santen Pharmaceutical Company Summary
7.17.2 Santen Pharmaceutical Business Overview
7.17.3 Santen Pharmaceutical Inherited Retinal Disease Treatment Major Product Offerings
7.17.4 Santen Pharmaceutical Inherited Retinal Disease Treatment Sales and Revenue in Global (2018-2023)
7.17.5 Santen Pharmaceutical Key News & Latest Developments
7.18 He Eye Hospital
7.18.1 He Eye Hospital Company Summary
7.18.2 He Eye Hospital Business Overview
7.18.3 He Eye Hospital Inherited Retinal Disease Treatment Major Product Offerings
7.18.4 He Eye Hospital Inherited Retinal Disease Treatment Sales and Revenue in Global (2018-2023)
7.18.5 He Eye Hospital Key News & Latest Developments
7.19 Bgi Genomics
7.19.1 Bgi Genomics Company Summary
7.19.2 Bgi Genomics Business Overview
7.19.3 Bgi Genomics Inherited Retinal Disease Treatment Major Product Offerings
7.19.4 Bgi Genomics Inherited Retinal Disease Treatment Sales and Revenue in Global (2018-2023)
7.19.5 Bgi Genomics Key News & Latest Developments
8 Global Inherited Retinal Disease Treatment Production Capacity, Analysis
8.1 Global Inherited Retinal Disease Treatment Production Capacity, 2018-2029
8.2 Inherited Retinal Disease Treatment Production Capacity of Key Manufacturers in Global Market
8.3 Global Inherited Retinal Disease Treatment Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Inherited Retinal Disease Treatment Supply Chain Analysis
10.1 Inherited Retinal Disease Treatment Industry Value Chain
10.2 Inherited Retinal Disease Treatment Upstream Market
10.3 Inherited Retinal Disease Treatment Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Inherited Retinal Disease Treatment Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer